Lymphocyte-mediated Immune Regulation in Health and Disease: The Treg and γδ T Cell Co-conspiracy

References

• Bates GJ, Fox SB, Han C, et al. (2006). Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol Off J Am Soc Clin Oncol, 24(34), 5373–5380.
   Google Scholar
• Bettelli E, Dastrange M, Oukka M. (2005). Foxp3 interacts with nuclear factor of activated T cells and NF-kappa B to repress cytokine gene expression and effector functions of T helper cells. Proc Natl Acad Sci USA, 102(14), 5138–5143.
   PubMed Web of Science ®Google Scholar
• Brunkow ME, Jeffery EW, Hjerrild KA, et al. (2001). Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat Genet, 27(1), 68–73.
   Google Scholar
• Casetti R, Agrati C, Wallace M, et al. (2009). Cutting edge: TGF-beta1 and IL-15 Induce FOXP3+ gammadelta regulatory T cells in the presence of antigen stimulation. J Immunol (Baltimore, MD, 1950), 183(6), 3574–3577.
   PubMed Web of Science ®Google Scholar
• Chevalier MF, Weiss L. (2013). The split personality of regulatory T cells in HIV infection. Blood, 121(1), 29–37.
   Google Scholar
• Coffelt SB, Kersten K, Doornebal CW, et al. (2015). IL-17-producing gammadelta T cells and neutrophils conspire to promote breast cancer metastasis. Nature, 522(7556), 345–348.
   PubMed Web of Science ®Google Scholar
• Curiel TJ, Coukos G, Zou L, et al. (2004). Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med, 10(9), 942–949.
   Google Scholar
• Deryugina EI, Zajac E, Juncker-Jensen A, et al. (2014). Tissue-infiltrating neutrophils constitute the major in vivo source of angiogenesis-inducing MMP-9 in the tumor microenvironment. Neoplasia (New York, NY), 16(10), 771–788.
   PubMed Web of Science ®Google Scholar
• Eruslanov EB, Bhojnagarwala PS, Quatromoni JG, et al. (2014). Tumor-associated neutrophils stimulate T cell responses in early-stage human lung cancer. J Clin Invest, 124(12), 5466–5480.
   Google Scholar
• Fontenot JD, Gavin MA, Rudensky AY. (2003). Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol, 4(4), 330–336.
   PubMed Web of Science ®Google Scholar
• Fridlender ZG, Albelda SM. (2012). Tumor-associated neutrophils: Friend or foe? Carcinogenesis, 33(5), 949–955.
   Google Scholar
• Gao Q, Qiu SJ, Fan J, et al. (2007). Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol Off J Am Soc Clin Oncol, 25(18), 2586–2593.
   Google Scholar
• Godfrey VL, Wilkinson JE, Rinchik EM, Russell LB. (1991). Fatal lymphoreticular disease in the scurfy (sf) mouse requires T cells that mature in a sf thymic environment: Potential model for thymic education. Proc Natl Acad Sci USA, 88(13), 5528–5532.
   Google Scholar
• Godfrey VL, Wilkinson JE, Russell LB. (1991). X-linked lymphoreticular disease in the scurfy (sf) mutant mouse. Am J Pathol, 138(6), 1379–1387.
   Google Scholar
• Griffiths RW, Elkord E, Gilham DE, et al. (2007). Frequency of regulatory T cells in renal cell carcinoma patients and investigation of correlation with survival. Cancer Immunol Immunother CII, 56(11), 1743–1753.
   Google Scholar
• Harly C, Guillaume Y, Nedellec S, et al. (2012). Key implication of CD277/butyrophilin-3 (BTN3A) in cellular stress sensing by a major human gammadelta T-cell subset. Blood, 120(11), 2269–2279.
   PubMed Web of Science ®Google Scholar
• Hearps AC, Martin GE, Rajasuriar R, Crowe SM. (2014). Inflammatory co-morbidities in HIV+ individuals: Learning lessons from healthy ageing. Curr HIV/AIDS Rep, 11(1), 20–34.
   Google Scholar
• Hiraoka N, Onozato K, Kosuge T, Hirohashi S. (2006). Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin Cancer Res Off J Am Assoc Cancer Res, 12(18), 5423–5434.
   PubMed Web of Science ®Google Scholar
• Hori S, Nomura T, Sakaguchi S. (2003). Control of regulatory T cell development by the transcription factor Foxp3. Sci (New York, NY), 299(5609), 1057–1061.
   Google Scholar
• Hua F, Kang N, Gao YA, et al. (2013). Potential regulatory role of in vitro-expanded Vdelta1 T cells from human peripheral blood. Immunol Res, 56(1), 172–180.
   PubMed Web of Science ®Google Scholar
• Huang B, Pan PY, Li Q, et al. (2006). Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res, 66(2), 1123–1131.
   PubMed Web of Science ®Google Scholar
• Iida N, Dzutsev A, Stewart CA, et al. (2013). Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Sci (New York, NY), 342(6161), 967–970.
   PubMed Web of Science ®Google Scholar
• Kang N, Tang L, Li X, et al. (2009). Identification and characterization of Foxp3(+) gammadelta T cells in mouse and human. Immunol Lett, 125(2), 105–113.
   PubMed Web of Science ®Google Scholar
• Khaitan A, Kravietz A, Mwamzuka M, et al. (2016). FOXP3+Helios+ regulatory T cells, immune activation and advancing disease in HIV infected children. J Acquir Immune Defic Syndr, 72(5), 474–484.
   PubMed Web of Science ®Google Scholar
• Kuhl AA, Pawlowski NN, Grollich K, et al. (2009). Human peripheral gammadelta T cells possess regulatory potential. Immunology, 128(4), 580–588.
   Google Scholar
• Ladoire S, Martin F, Ghiringhelli F. (2011). Prognostic role of FOXP3+ regulatory T cells infiltrating human carcinomas: The paradox of colorectal cancer. Cancer Immunol Immunother CII, 60(7), 909–918.
   PubMed Web of Science ®Google Scholar
• Lai C, August S, Albibas A, et al. (2016). OX40+ regulatory T cells in cutaneous squamous cell carcinoma suppress effector T cell responses and associate with metastatic potential. Clin Cancer Res Off [Epub ahead of print].
   Google Scholar
• Legut M, Cole DK, Sewell AK. (2015). The promise of gammadelta T cells and the gammadelta T cell receptor for cancer immunotherapy. Cell Mol Immunol, 12(6), 656–668.
   Google Scholar
• Li B, Samanta A, Song X, et al. (2007). FOXP3 interactions with histone acetyltransferase and class II histone deacetylases are required for repression. Proc Natl Acad Sci USA, 104(11), 4571–4576.
   PubMed Web of Science ®Google Scholar
• Manjili MH. (2012). Phenotypic plasticity of MDSC in cancers. Immunol Invest, 41(6–7), 711–721.
   Google Scholar
• Marvel D, Gabrilovich DI. (2015). Myeloid-derived suppressor cells in the tumor microenvironment: Expect the unexpected. J Clin Invest, 125(9), 3356–3364.
   Google Scholar
• Mercer F, Khaitan A, Kozhaya L, et al. (2014). Differentiation of IL-17-producing effector and regulatory human T cells from lineage-committed naive precursors. J Immunol (Baltimore, Md.: 1950), 193(3), 1047–1054.
   PubMed Web of Science ®Google Scholar
• Mishalian I, Bayuh R, Eruslanov E, et al. (2014). Neutrophils recruit regulatory T-cells into tumors via secretion of CCL17–a new mechanism of impaired antitumor immunity. Int J Cancer, 135(5), 1178–1186.
   PubMed Web of Science ®Google Scholar
• Miyara M, Yoshioka Y, Kitoh A, et al. (2009). Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity 30(6), 899–911.
   PubMed Web of Science ®Google Scholar
• Mougiakakos D, Choudhury A, Lladser A, et al. (2010). Regulatory T cells in cancer. Adv Cancer Res, 107, 57–117.
   PubMed Web of Science ®Google Scholar
• Ono M, Yaguchi H, Ohkura N, et al. (2007). Foxp3 controls regulatory T-cell function by interacting with AML1/Runx1. Nature, 446(7136), 685–689.
   PubMed Web of Science ®Google Scholar
• Pan PY, Ma G, Weber KJ, et al. (2010). Immune stimulatory receptor CD40 is required for T-cell suppression and T regulatory cell activation mediated by myeloid-derived suppressor cells in cancer. Cancer Res, 70(1), 99–108.
   PubMed Web of Science ®Google Scholar
• Patel SS, Wacholtz MC, Duby AD, et al. (1989). Analysis of the functional capabilities of CD3+CD4-CD8- and CD3+CD4+CD8+ human T cell clones. J Immunol (Baltimore, MD, 1950), 143(4), 1108–1117.
   PubMed Web of Science ®Google Scholar
• Perrone G, Ruffini PA, Catalano V, et al. (2008). Intratumoural FOXP3-positive regulatory T cells are associated with adverse prognosis in radically resected gastric cancer. Eur J Cancer (Oxford, England: 1990), 44(13), 1875–1882.
   Google Scholar
• Peters C, Oberg HH, Kabelitz D, Wesch D. (2014). Phenotype and regulation of immunosuppressive Vdelta2-expressing gammadelta T cells. Cell Mol Life Sci CMLS, 71(10), 1943–1960.
   PubMed Web of Science ®Google Scholar
• Petersen RP, Campa MJ, Sperlazza J, et al. 2006. Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients. Cancer, 107(12), 2866–2872.
   PubMed Web of Science ®Google Scholar
• Rabinovich GA, Conejo-Garcia JR. (2016). Shaping the immune landscape in cancer by galectin-driven regulatory pathways. J Mol Biol [Epub ahead of print]. doi:10.1016/j.jmb.2016.03.021
   PubMed Web of Science ®Google Scholar
• Ren JP, Ying RS, Cheng YQ, et al. (2016). HCV-induced miR146a controls SOCS1/STAT3 and cytokine expression in monocytes to promote regulatory T-cell development. J Viral Hepatitis [ePub ahead of print]. doi:10.1111/jvh.12537
   Google Scholar
• Rezende RM, da Cunha AP, Kuhn C, et al. (2015). Identification and characterization of latency-associated peptide-expressing gammadelta T cells. Nat Commun, 6, 8726.
   PubMed Web of Science ®Google Scholar
• Rutkowski MR, Stephen TL, Svoronos N, et al. (2015). Microbially driven TLR5-dependent signaling governs distal malignant progression through tumor-promoting inflammation. Cancer cell, 27(1), 27–40.
   PubMed Web of Science ®Google Scholar
• Salama P, Phillips M, Grieu F, et al. (2009). Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol Off J Am Soc Clin Oncol, 27(2), 186–192.
   PubMed Web of Science ®Google Scholar
• Schipmann S, Wermker K, Schulze HJ, et al. (2014). Cutaneous and oral squamous cell carcinoma-dual immunosuppression via recruitment of FOXP3+ regulatory T cells and endogenous tumour FOXP3 expression? J Cranio-Maxillo-Facial Surgery Off Publ Eur Assoc Cranio-Maxillo-Facial Surgery, 42(8), 1827–1833.
   PubMed Web of Science ®Google Scholar
• Schlecker E, Stojanovic A, Eisen C, et al. (2012). Tumor-infiltrating monocytic myeloid-derived suppressor cells mediate CCR5-dependent recruitment of regulatory T cells favoring tumor growth. J Immunol (Baltimore, Md.: 1950), 189(12), 5602–5611.
   PubMed Web of Science ®Google Scholar
• Serafini P, Mgebroff S, Noonan K, Borrello I. (2008). Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells. Cancer Res, 68(13), 5439–5449.
   Google Scholar
• Sumpter TL, Payne KK, Wilkes DS. (2008). Regulation of the NFAT pathway discriminates CD4+CD25+ regulatory T cells from CD4+CD25- helper T cells. J Leukocyte Biol, 83(3), 708–717.
   PubMed Web of Science ®Google Scholar
• Toia F, Buccheri S, Anfosso A, et al. (2016). Skewed differentiation of circulating Vgamma9Vdelta2 T lymphocytes in melanoma and impact on clinical outcome. PloS One, 11(2), e0149570.
   Web of Science ®Google Scholar
• Uribe-Querol E, Rosales C. (2015). Neutrophils in cancer: Two sides of the same coin. J Immunol Res, 2015, 983698.
   PubMedGoogle Scholar
• Vaeth M, Schliesser U, Muller G, et al. (2012). Dependence on nuclear factor of activated T-cells (NFAT) levels discriminates conventional T cells from Foxp3+ regulatory T cells. Proc Natl Acad Sci USA, 109(40), 16258–16263.
   PubMed Web of Science ®Google Scholar
• Vavassori S, Kumar A, Wan GS, et al. (2013). Butyrophilin 3A1 binds phosphorylated antigens and stimulates human gammadelta T cells. Nat Immunol, 14(9), 908–916.
   PubMed Web of Science ®Google Scholar
• Viaud S, Saccheri F, Mignot G, et al. (2013). The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Sci (New York, NY), 342(6161), 971–976.
   PubMed Web of Science ®Google Scholar
• Vignali D. (2008). How many mechanisms do regulatory T cells need? Eur J Immunol, 38(4), 908–911.
   Google Scholar
• von Lilienfeld-Toal M, Nattermann J, Feldmann G, et al. (2006). Activated gammadelta T cells express the natural cytotoxicity receptor natural killer p 44 and show cytotoxic activity against myeloma cells. Clin Exp Immunol, 144(3), 528–533.
   PubMed Web of Science ®Google Scholar
• Wang J, Ioan-Facsinay A, van der Voort EI, et al. (2007). Transient expression of FOXP3 in human activated nonregulatory CD4+ T cells. Eur J Immunol, 37(1), 129–138.
   PubMed Web of Science ®Google Scholar
• Wu D, Wu P, Wu X, et al. (2015). Expanded human circulating Vdelta1 gammadeltaT cells exhibit favorable therapeutic potential for colon cancer. Oncoimmunology, 4(3), e992749.
   PubMed Web of Science ®Google Scholar
• Ye J, Ma C, Wang F, et al. (2013). Specific recruitment of gammadelta regulatory T cells in human breast cancer. Cancer Res, 73(20), 6137–6148.
   Google Scholar
• Zhou SL, Zhou ZJ, Hu ZQ,et al. (2016). Tumor-associated neutrophils recruit macrophages and T-regulatory cells to promote progression of hepatocellular carcinoma and resistance to Sorafenib. Gastroenterology, 150(7), 1646–1658.
   PubMed Web of Science ®Google Scholar